Lithium containing aluminosilicate glasses

Patent metadata

Field	Value
Publication number	US-10640415-B2
Application number	US-201715825793-A
Country	US
Kind code	B2
Filing date	Nov 29, 2017
Priority date	Nov 30, 2016
Publication date	May 5, 2020
Grant date	May 5, 2020

Abstract

A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO 2 , from 4.00 mol % to 11.00 mol % Al 2 O 3 , from 0.10 mol % to 16.00 mol % Li 2 O, from 0.10 mol % to 12.00 mol % Na 2 O, from 0.00 mol % to 5.00 mol % K 2 O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may be substantially free of B 2 O 3 , SrO, BaO, and ZrO 2 .

First claim

What is claimed is:

1. A glass pharmaceutical package having a glass composition comprising:
from greater than or equal to 68.00 mol % to less than or equal to 81.00 mol % SiO 2 ;
from greater than or equal to 4.00 mol % to less than or equal to 11.00 mol % Al 2 O 3 ;
from greater than or equal to 0.10 mol % to less than or equal to 16.00 mol % Li 2 O;
from greater than or equal to 0.10 mol % to less than or equal to 12.00 mol % Na 2 O;
from greater than or equal to 0.00 mol % to less than or equal to 5.00 mol % K 2 O;
from greater than or equal to 0.10 mol % to less than or equal to 8.00 mol % MgO;
from greater than or equal to 0.10 mol % to less than or equal to 5.00 mol % CaO;
from greater than or equal to 0.00 mol % to less than or equal to 0.20 mol % fining agent, wherein
the glass pharmaceutical package is delamination resistant,
the glass pharmaceutical package has class 1 or class 2 chemical durability in acid, base, and water,
the amount of Li 2 O relative to the total alkali metal content is from greater than or equal to 60% to less than or equal to 70%, and
the amount of Na 2 O to the total alkali metal content is from greater than or equal to 12% to less than or equal to 22%.

2. The glass pharmaceutical package according to claim 1 , wherein the glass composition comprises greater than 0.00 mol % of the fining agent, and the fining agent is selected from the group consisting of SnO 2 , CeO 2 , As 2 O 3 , Sb 2 O 3 , Cl − , S − , F − , or Fe 2 O 3 .

3. The glass pharmaceutical package according to claim 2 , wherein the fining agent consists of SnO 2 .

4. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is substantially free of at least one of B 2 O 3 , SrO, BaO, ZrO 2 .

5. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is substantially free of B 2 O 3 , SrO, BaO, and ZrO 2 .

6. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises from greater than or equal to 1.50 mol % to less than or equal to 16.00 mol % Li 2 O.

7. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises from greater than or equal to 0.10 mol % to less than or equal to 7.50 mol % MgO.

8. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a ratio of (Li 2 O+Na 2 O+K 2 O)/(SiO 2 +Al 2 O 3 ) that is from greater than or equal to 0.05 to less than or equal to 0.50.

9. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a ratio of (Li 2 O+Na 2 O+K 2 O)/(SiO 2 +Al 2 O 3 ) that is from greater than or equal to 0.05 to less than or equal to 0.15.

10. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a density from greater than or equal to 2.25 g/cm 3 to less than or equal to 2.50 g/cm 3 .

11. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a molar volume from greater than or equal to 24.00 cm 3 /mol to less than or equal to 27.00 cm 3 /mol.

12. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package has a delamination factor less than or equal to 10.

13. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a strain point from greater than or equal to 450° C. to less than or equal to 625° C.

14. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises an annealing point from greater than or equal to 500° C. to less than or equal to 675° C.

15. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a softening point from greater than or equal to 750° C. to less than or equal to 950° C.

16. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a coefficient of thermal explanation (CTE) from greater than or equal to 4.20 ppm/° C. to less than or equal to 7.00 ppm/° C.

17. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a Log of liquidus viscosity from greater than or equal to 3.50 poise to less than or equal to 6.00 poise.

18. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a Young's modulus from greater than or equal to 10.00 mpsi to less than or equal to 12.00 mpsi.

19. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a shear modulus from greater than or equal to 4.00 mpsi to less than or equal to 5.00 mpsi.

20. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in acid as measured by DIN 12116 from greater than or equal to 0.0 mg/dm 2 to less than or equal to 1.5 mg/dm 2 .

21. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in acid as measured by DIN 12116 from greater than or equal to 0.0 mg/dm 2 to less than or equal to 0.7 mg/dm 2 .

22. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in base as measured by ISO 695 from greater than or equal to 0 mg/dm 2 to less than or equal to 175 mg/dm 2 .

23. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in base as measured by ISO 695 from greater than or equal to 0 mg/dm 2 to less than or equal to 75 mg/dm 2 .

24. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in water as measured by ISO 720 from greater than or equal to 0 μg/g to less than or equal to 100 μg/g.

25. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in water as measured by ISO 720 from greater than or equal to 0 μg/g to less than or equal to 62 μg/g.

26. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a surface compressive stress of at least 350 MPa.

27. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a depth of compression from greater than or equal to 0.05t to less than or equal to 0.25t.

28. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a central tension from greater than or equal to 5 MPa to less than or equal to 160 MPa.

29. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a diffusivity of potassium ions at 420° C. is from greater than or equal to 0.50 μm 2 /hr to less than or equal to 15.00 μm 2 /hr.

30. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a stored energy of less than or

Assignees

• Corning Inc

Inventors

• Demartino Steven Edward
• Lönnroth Nadja Teresia
• Ma Lina
• Schaut Robert Anthony
• Smith Charlene Marie
• Tang Zhongzhi
• Westbrook Jamie Todd

Classifications

• C03C21/002

  to perform ion-exchange between alkali ions (C03C21/005 takes precedence) · CPC title

• C03C3/076

  with 40% to 90% silica, by weight {(C03C3/045 takes precedence)} · CPC title

• A61J1/00

  Containers specially adapted for medical or pharmaceutical purposes (capsules or the like for oral use A61J3/07; specially adapted for surgical or diagnostic appliances or instruments A61B50/30; containers for radioactive substances G21F5/00) · CPC title

• C03C3/078

  containing an oxide of a divalent metal, e.g. an oxide of zinc · CPC title

• C03C3/083

  containing aluminium oxide or an iron compound · CPC title